Congressional Leaders Ask FDA About Coumadin Safety

[fusion_builder_container hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" enable_mobile="no" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" overlay_opacity="0.5" border_style="solid" padding_top="20px" padding_bottom="20px"][fusion_builder_row][fusion_builder_column type="1_1" spacing="" center_content="no" hover_type="none" link="" min_height="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" class="" id="" background_color="" background_image="" background_position="left top" background_repeat="no-repeat" border_size="0" border_color="" border_style="solid" border_position="all" padding="" dimension_margin="undefined" animation_type="" animation_direction="left" animation_speed="0.3" animation_offset="" last="no"][fusion_text]

The bipartisan leadership of the House Energy and Commerce Committee is asking the Food and Drug Administration how it monitors the safety of the popular blood thinner Coumadin, particularly in light of deaths and hospitalizations of nursing home residents taking the drug.

The full story can be read HERE. The Committee's letter can be read HERE.

[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

All consultations are free. Contacting our firm to discuss your potential case does not result in any expense to you.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram